Heparin-induced thrombocytopenia type II (HIT II), a well-known and serious complication of heparin treatment, is mediated by antibodies directed against heparin/platelet factor 4 complexes (1,2). These antibodies, the vast majority of which belong to the immunoglobulin G (IgG) class, are capable of activating platelets via the FcγIIA receptor (3, 4) . The clinical significance of IgM and IgA antibodies to heparin/platelet factor 4 (HPF4) complexes is yet unclear (5-7). Here, we describe a patient with HIT II in whom only heparin-dependent antibodies of the IgA class could be detected. platelet activation assay (HIPA) and by the ID-HPF4 particle agglutination assay. The flow cytometric analysis showed that the antibody was of the IgA class.
CASE REPORT
The patient was a 61-year-old man who underwent aortocoronary bypass surgery and re-ceived postoperative heparin therapy. His platelet count, which had been 308∞10 3 /µL before surgery, dropped to 162∞10 3 /µL by day 4 and reincreased to 276∞10 3 /µL by day 8. On day 10, the patient developed an acute abdomen, and cecal fistula was required. A subxyphoidal hematoma had to be drained on day 11. The patient felt well after surgery, but his platelet count continued to fall, reaching 57∞10 3 /µL by day 15. The patient was then diagnosed with HIT II. He was therefore taken off heparin and switched to Refludan ® (Schering, Berlin, Germany). The platelet count had risen to 197∞10 3 /µL by day 25, but an acute pulmonary embolism developed, and the patient died of refractory multiorgan failure on day 26 ( Fig. 1 ).
MATERIALS AND METHODS

Serologic Investigation
The patient's serum (obtained on day 14) was tested by means of heparin-induced platelet activation assay (HIPA) (8) and ID-HPF4 particle gel immunoassay (DiaMed, Cressier sur Morat, Switzerland) (9). The immunoglobulin classes Summary: Heparin-induced thrombocytopenia type II (HIT II) is usually mediated by immunoglobulin G (IgG) antibodies that lead to platelet activation via the FcγIIA-receptor. Here we describe a patient who developed HIT II after aortocoronary bypass surgery. His serum contained an antibody that was detectable by the heparin-induced were identified by flow cytometry using ID-HPF4 particles and fluorescein isothiocyanate (FITC) conjugated antihuman antibodies (10) . For the detection of IgG-antibodies 10 µL of a goat-antihuman-IgG (Beckman Coulter, Krefeld, Germany) were used, for IgA-and IgM-antibodies, 10 µL each (rabbit-anti-human DAKO, Hamburg, Germany). The fluorescence was evaluated by using an Epics XL flow cytometer (Beckman Coulter, Krefeld, Germany). Serum samples from healthy volunteers served as negative controls.
RESULTS
Patient's serum reacted with platelets from 4 different donors in the presence of therapeutic concentrations of heparin (0.2 IU/mL), but not in the absence or in the presence of excessive concentrations of heparin (100 IU/mL). In addition, it showed strong agglutinations of HPF4 particles. Flow cytometric analysis of the IHPF4 par-ticles preincubated with patient's serum revealed positivity with anti-IgA, but not with anti-IgG or anti-IgM (Fig. 2 ).
DISCUSSION
The patient described here clearly developed a case of HIT II that resulted in pulmonary embolism and death. The patient's platelet count decreased from 276∞10 3 /µL on day 8 to 57∞10 3 /µL by day 15, but rose again after heparin was discontinued and Refludan ® was initiated. The patient's serum contained antibodies to HPF4 complexes that were detectable by HIPA and ID-HPF4. Based on the flow cytometric analysis, all of the antibodies were of the IgA class. This finding indicates that IgA antibodies may indeed be able to induce significant HIT II. The question of how these antibodies activate platelets remains obscure . Whatever the mechanism may be, IgA antibodies should not be excluded from the work-up of HIT-II. 
